Yuhan Corporation is a global pharmaceutical enterprise specializing in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and intermediate compounds, with operations spanning South Korea and international markets. Its extensive product portfolio includes a diverse range of pharmaceuticals such as antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds. A notable offering is Revanex, an acid pump antagonist used to treat peptic ulcers and gastritis-related mucosal damage. The company also provides ethical drugs (ETC) targeting multiple therapeutic areas, including cardiovascular, digestive, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, hormone therapies, analgesics, anti-rheumatics, and anesthetics. Beyond prescription medications, Yuhan also markets over-the-counter (OTC) items, encompassing vitamins, minerals, liver support medications, tonics, and remedies for respiratory, digestive, dermatological, and pain conditions. Furthermore, it supplies household and personal care goods, such as cleaning agents (bleaches, detergents), pest control products, and oral hygiene solutions. The corporation maintains a dental division, supplying implants, dental equipment, consumables, and general dental care products. Animal health is another segment, with the company producing and distributing veterinary medical supplies for livestock, aquatic species, and domestic pets. Contract manufacturing services are also available through Yuhan. Established in 1926, Yuhan Corporation is headquartered in Seoul, South Korea.
www.yuhan.co.krβ- Employees
- 2,153
- IPO / List date
- Sep 29, 2005
- HQ
- KR